drugset / Trial / NCT00194467
Suppression of Oral HHV8 Shedding With Valganciclovir
RandomizedCrossoverDouble-blindPrevention
Summary
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in the mouth.
Timeline
- Start
- 2002-12
- Primary completion
- 2005-03
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valganciclovir | Small molecule | 900 mg | — |